Fwd: Recommended articles
9 views
Skip to first unread message
Okechukwu Ogah
Apr 7, 2024, 2:34:11 PMApr 7
to nigerian-car...@googlegroups.com
Dr O.S Ogah. MBBS, MSc, PhD, MD, FWACP, FACP, FESC, FNCS
A. Senior Lecturer
Cardiology Unit, Department of Medicine,
Faculty of Clinical Sciences
College of Medicine,
University of Ibadan, NIGERIA
B. Honorary Consultant Physician/Cardiologist,
Cardiology Unit,
Department of Medicine
University College Hospital Ibadan, NIGERIA
PERSONAL POSTAL ADDRESS
P.O BOX 14343, UNIVERSITY OF IBADAN POST OFFICE
IBADAN, NIGERIA
C. Bernard Lown Visiting Scholar in Cardiovascular Health
Department of Global Health and Population
Harvard T.H. Chan School of Public Health
Email: oo...@hsph.harvard.edu
D. Adjunct Researcher,
Institute of Advanced Medical Research and Training (IAMRAT)
College of Medicine, University of Ibadan, NIGERIA
E. Affiliate Member,
The Hatter Institute for Cardiovascular Research in Africa (HICRA)
4th Floor Chris Barnard Building
Faculty of Health Sciences
University of Cape Town
Private Bag X3 7935
Observatory, SOUTH AFRICA
Faculty of Health Sciences
University of Cape Town
Private Bag X3 7935
Observatory, SOUTH AFRICA
F. Past President,
Nigerian Cardiac Society
--------------------------------------------------------------------------------------------------------------------------------------------------
"For with thee is the fountain of life: in thy light shall we see light." Psalm 36:9
-------------------------------------------------------------------------------------------------
---------- Forwarded message ---------
From: Google Scholar Alerts <scholarale...@google.com>
Date: Sun, Apr 7, 2024 at 8:59 AM
Subject: Recommended articles
To: <osoga...@gmail.com>
From: Google Scholar Alerts <scholarale...@google.com>
Date: Sun, Apr 7, 2024 at 8:59 AM
Subject: Recommended articles
To: <osoga...@gmail.com>
[PDF] Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
D D'Amario, R Laborante, E Bianchini, G Ciliberti… - ESC heart failure, 2024
Aims Several mechanisms have been identified in the aetiopathogenesis of heart
failure with preserved ejection fraction (HFpEF). Among these, coronary
microvascular dysfunction (CMD) may play a key pathophysiological role. We …
failure with preserved ejection fraction (HFpEF). Among these, coronary
microvascular dysfunction (CMD) may play a key pathophysiological role. We …
 |  |  |  |
One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction
R Sato, S von Haehling - Med, 2024
While bodyweight reduction should be a primary intervention target in obese heart
failure with preserved ejection fraction (HFpEF) patients, no pharmacological
treatments have shown evidence. The STEP HFpEF trial 1 showed that semaglutide …
failure with preserved ejection fraction (HFpEF) patients, no pharmacological
treatments have shown evidence. The STEP HFpEF trial 1 showed that semaglutide …
| | | |
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support System
EM Foster, JC Coons, EA Puccio, D Sullinger… - Annals of Pharmacotherapy, 2024
Background: Despite atrial fibrillation guideline recommendations, many patients
with heart failure with reduced ejection fraction (EF) continue to receive IV diltiazem
for acute rate control. Objective: Our institution recently implemented a clinical …
with heart failure with reduced ejection fraction (EF) continue to receive IV diltiazem
for acute rate control. Objective: Our institution recently implemented a clinical …
| | | |
[PDF] Heart failure with preserved and reduced ejection fraction: comorbidities, therapies and cause-specific outcomes
A Shahim - 2024
Background: Heart failure (HF) is associated with worse prognosis and poor quality
of life, and its rising global prevalence puts a growing strain on healthcare systems.
While most previous studies have focused on cardiovascular (CV) comorbidities and …
of life, and its rising global prevalence puts a growing strain on healthcare systems.
While most previous studies have focused on cardiovascular (CV) comorbidities and …
| | | |
[HTML] Unlocking the potential of sacubitril/valsartan therapy in improving ECG and echocardiographic parameters in heart failure patients with reduced ejection fraction …
LE Allam, AA Abdelmotteleb, HM Eldamanhoury… - The Egyptian Heart Journal, 2024
Background Sacubitril/valsartan therapy has been found to reduce hospitalizations,
improve echocardiogram parameters, and improve mortality in HFrEF. The objective
is to assess S/V therapy effect on electrocardiogram indices and how those …
improve echocardiogram parameters, and improve mortality in HFrEF. The objective
is to assess S/V therapy effect on electrocardiogram indices and how those …
| | | |
[HTML] Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin …
F Simko, P Stanko, K Repova, T Baka, K Krajcirovicova… - Biomedicine & …, 2024
This study investigated whether sacubitril/valsartan or valsartan are able to prevent
left ventricular (LV) fibrotic remodelling and dysfunction in two experimental models
of pre-hypertension induced by continuous light (24 hours/day) exposure or by …
left ventricular (LV) fibrotic remodelling and dysfunction in two experimental models
of pre-hypertension induced by continuous light (24 hours/day) exposure or by …
| | | |
[HTML] Minimally invasive left atrial appendage occlusion plus reduced dose direct oral anticoagulant to prevent stroke in patients with atrial fibrillation—the LAAO-PlusRE
L Besola, D Gregori, A Fiocco, A Colli - Annals of Cardiothoracic Surgery, 2024
The onset of atrial fibrillation (AF) has a direct association with left atrial appendage
(LAA) function, as demonstrated by recent studies demonstrating the link between
left atrial (LA) wall fibrosis, impaired contractility, and the development of AF. Non …
(LAA) function, as demonstrated by recent studies demonstrating the link between
left atrial (LA) wall fibrosis, impaired contractility, and the development of AF. Non …
| | | |
See all recommendations
This message was sent by Google Scholar because you're following new recommended articles for your profile.
Okechukwu Ogah
Apr 8, 2024, 10:59:48 AMApr 8
to nigerian-car...@googlegroups.com
[HTML] Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1
B Li, WW Bai, T Guo, ZY Tang, XJ Jing, TC Shan, S Yin… - Nature Communications, 2024
Heart failure with preserved ejection fraction (HFpEF) is associated with endothelial
dysfunction. We have previously reported that statins prevent endothelial dysfunction
through inhibition of microRNA-133a (miR-133a). This study is to investigate the …
dysfunction. We have previously reported that statins prevent endothelial dysfunction
through inhibition of microRNA-133a (miR-133a). This study is to investigate the …
| | | |
EMULATION OF A TARGET TRIAL ESTIMATING THE CAUSAL RELATIONSHIP BETWEEN MEDICATION ADHERENCE TO SACUBITRIL/VALSARTAN AND …
A Ray, J Lauffenburger, R Desai - Journal of the American College of Cardiology, 2024
Background We aimed to emulate a target trial to estimate the causal relationship
between medication adherence to Sacubitril/Valsartan (SAC/VAL) and adverse
clinical outcomes in heart failure with reduced ejection fraction (HFrEF). Methods …
between medication adherence to Sacubitril/Valsartan (SAC/VAL) and adverse
clinical outcomes in heart failure with reduced ejection fraction (HFrEF). Methods …
| | | |
THE INFLUENCE OF DAPAGLIFLOZIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
AA Much, S Hamzi, A Fardman, E Massalha… - Journal of the American …, 2024
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown
to decrease mortality and morbidity in patients with heart failure with reduced
ejection fraction (HFrEF). One of the proposed mechanisms contributing to the …
to decrease mortality and morbidity in patients with heart failure with reduced
ejection fraction (HFrEF). One of the proposed mechanisms contributing to the …
| | | |
IN-HOSPITAL OR OUT-OF-HOSPITAL INITIATION OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN IN PATIENTS WITH MILDLY REDUCED OR PRESERVED …
N Nouhravesh, T Erickson, DD Cyr, AF Hernandez… - Journal of the American …, 2024
Background Limited data are found on effects and tolerability of sacubitril/valsartan
(Sac/Val) according to location of initiation in heart failure (HF) with ejection fraction
(EF)> 40%. This pre-specified PARAGLIDE-HF analysis, assessed effects of Sac/Val …
(Sac/Val) according to location of initiation in heart failure (HF) with ejection fraction
(EF)> 40%. This pre-specified PARAGLIDE-HF analysis, assessed effects of Sac/Val …
| | | |
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis
KM Talha, J Green, G Filippatos, S Pocock, F Zannad… - Diabetes, Obesity and …, 2024
Aim To assess the effect of empagliflozin on patients with comorbid heart failure (HF)
and diabetes with or without baseline insulin, and to study the impact of
empagliflozin on insulin requirements over time. Materials and Methods We …
and diabetes with or without baseline insulin, and to study the impact of
empagliflozin on insulin requirements over time. Materials and Methods We …
| | | |
[HTML] Global longitudinal strain in long-term risk prediction after acute coronary syndrome: an investigation of added prognostic value to ejection fraction
J Lenell, B Lindahl, D Erlinge, T Jernberg, J Spaak… - Clinical Research in …, 2024
Aims This study aimed to investigate the additional value of global longitudinal strain
(GLS) on top of left ventricular ejection fraction (LVEF) in long-term risk prediction of
combined death and heart failure (HF) re-hospitalization after acute coronary …
(GLS) on top of left ventricular ejection fraction (LVEF) in long-term risk prediction of
combined death and heart failure (HF) re-hospitalization after acute coronary …
| | | |
SACUBITRIL/VALSARTAN, TREATMENT-RELATED HYPOTENSION, AND LEFT VENTRICULAR EJECTION FRACTION IN THE PARAGON-HF TRIAL
A Foà, B Claggett, M Pabon, H Lu, MA Pfeffer… - Journal of the American …, 2024
Background Hypotension is a common adverse event in patients treated with
sacubitril/valsartan. The benefit of sacubitril/valsartan has been limited to subjects
with LVEF below normal. We investigated if treatment-related hypotension varied by …
sacubitril/valsartan. The benefit of sacubitril/valsartan has been limited to subjects
with LVEF below normal. We investigated if treatment-related hypotension varied by …
| | | |
RIGHT VENTRICULAR DYSFUNCTION IN PERIPARTUM CARDIOMYOPATHY IS ASSOCIATED WITH ADVERSE CARDIOVASCULAR OUTCOMES AND LOWER …
AA Khan, F Fayad, CW Kim, F Ataklte, A Poppas… - Journal of the American …, 2024
Background Peripartum cardiomyopathy (PPCM) is a type of heart failure with
reduced ejection fraction occurring during late pregnancy or postpartum. Studies
have been inconsistent in the prognostic relevance of right ventricular (RV) …
reduced ejection fraction occurring during late pregnancy or postpartum. Studies
have been inconsistent in the prognostic relevance of right ventricular (RV) …
| | | |
RACIAL AND ETHNIC DIFFERENCES IN CARDIOVASCULAR OUTCOMES IN PATIENTS DIAGNOSED WITH HYPERTROPHIC CARDIOMYOPATHY
N Reza, K Batra, Q Amos, A Buikema, A Anderson… - Journal of the American …, 2024
Background Prior studies on the associations between race/ethnicity and
cardiovascular (CV) outcomes in patients with hypertrophic cardiomyopathy (HCM)
have been limited in size. Therefore, we investigated these associations in a large …
cardiovascular (CV) outcomes in patients with hypertrophic cardiomyopathy (HCM)
have been limited in size. Therefore, we investigated these associations in a large …
| | | |
EFFECT OF SACUBITRIL/VALSARTAN ACCORDING TO POLYPHARMACY STATUS IN PARAGON-HF
S Matsumoto, M Yang, L Shen, B Claggett, AS Desai… - Journal of the American …, 2024
Background Patients with heart failure and preserved ejection fraction (HFpEF) have
a particularly high prevalence of comorbidities, often necessitating treatment with a
large number of medications. This study examined the efficacy and safety of …
a particularly high prevalence of comorbidities, often necessitating treatment with a
large number of medications. This study examined the efficacy and safety of …
Okechukwu Ogah
Apr 8, 2024, 11:03:24 AMApr 8
to nigerian-car...@googlegroups.com
Okechukwu Ogah
Apr 8, 2024, 12:04:57 PMApr 8
to nigerian-car...@googlegroups.com
[HTML] Clinical Trajectory and Risk Stratification for Heart Failure with Preserved Ejection Fraction in a Real-World Cohort of Patients with Suspected Coronary Artery Disease
G Gioia, KP Kresoja, S Rosch, A Schöber, E Harnisch… - Journal of Clinical Medicine, 2024
Background: Heart failure with preserved ejection fraction (HFpEF) is a widespread
condition with significant morbidity and mortality. Its clinical heterogeneity may delay
the diagnosis. Aim: To identify predictors of HFpEF-related hospitalizations in …
condition with significant morbidity and mortality. Its clinical heterogeneity may delay
the diagnosis. Aim: To identify predictors of HFpEF-related hospitalizations in …
| | | |
[PDF] Association of hypertension burden with stroke risk in patients with heart failure with preserved ejection fraction
S Guo, X Liu, Z Gu, J Sun, Y Cao, W Zhu - Heliyon, 2024
Introduction Whether the hypertension burden is associated with stroke incidence is
inconclusive. In this study, we aimed to investigate the relationship between
hypertension burden and stroke risk in patients with heart failure with preserved …
inconclusive. In this study, we aimed to investigate the relationship between
hypertension burden and stroke risk in patients with heart failure with preserved …
| | | |
[HTML] Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
W Guo, L Zhao, W Huang, J Chen, T Zhong, S Yan… - Cardiovascular Diabetology, 2024
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are increasingly recognized for
their role in reducing the risk and improving the prognosis of heart failure (HF).
However, the precise mechanisms involved remain to be fully delineated. Evidence …
their role in reducing the risk and improving the prognosis of heart failure (HF).
However, the precise mechanisms involved remain to be fully delineated. Evidence …
| | | |
Left ventricular trabeculations at cardiac MRI: reference ranges and association with cardiovascular risk factors in UK Biobank
N Aung, A Bartoli, E Rauseo, S Cortaredona… - Radiology, 2024
Background The extent of left ventricular (LV) trabeculation and its relationship with
cardiovascular (CV) risk factors is unclear. Purpose To apply automated
segmentation to UK Biobank cardiac MRI scans to (a) assess the association …
cardiovascular (CV) risk factors is unclear. Purpose To apply automated
segmentation to UK Biobank cardiac MRI scans to (a) assess the association …
| | | |
[HTML] Isolated Ventricular Noncompaction in a Patient with a Sarcomeric Gene Mutation: A Case Report
S Guntaka, MR Alston, D Gruber, BM Azari - HeartRhythm Case Reports
Discussion: Trabeculations within the developing heart increase myocardial mass
and contribute to coordinated contractility. Ontogenesis progresses with the
trabeculations compacting into the myocardium, however, pathological persistence …
and contribute to coordinated contractility. Ontogenesis progresses with the
trabeculations compacting into the myocardium, however, pathological persistence …
| | | |
[HTML] Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases?
SE Kjeldsen, BM Egan, M Burnier, K Narkiewicz… - Blood Pressure, 2024
The 2023 Guidelines of the European Society of Hypertensin (ESH)[1] contain
several novelties though numerous ground pillars in the management of
hypertension remain as before. For example, treatment of masked hypertension may …
several novelties though numerous ground pillars in the management of
hypertension remain as before. For example, treatment of masked hypertension may …
| | | |
[HTML] Rheumatic Heart Disease: A Rare Cause of Very Severe Valvular Aortic Stenosis
L Alizadeh, F Peters, AF Vainrib, RS Freedberg… - CASE, 2024
From the Leon H. Charney Division of Cardiology, NYU Grossman School of
Medicine, NYU Langone Health, New York, New York (LA, AFV, RSF, MS); and
Division of Cardiology, Chris Hani Baragwanath Hospital, University of the …
Medicine, NYU Langone Health, New York, New York (LA, AFV, RSF, MS); and
Division of Cardiology, Chris Hani Baragwanath Hospital, University of the …
| | | |
[HTML] Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
JH Butt, PS Jhund, KF Docherty, BL Claggett… - JACC: Heart Failure, 2024
Background Patients recently hospitalized for heart failure (HF) are at a higher risk of
adverse clinical outcomes, but they may experience a greater absolute and relative
benefit from effective therapies than individuals who are considered more “stable.” …
adverse clinical outcomes, but they may experience a greater absolute and relative
benefit from effective therapies than individuals who are considered more “stable.” …
Okechukwu Ogah
Apr 10, 2024, 7:16:15 AMApr 10
to nigerian-car...@googlegroups.com
[PDF] Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
D D'Amario, R Laborante, E Bianchini, G Ciliberti… - ESC heart failure, 2024
Aims Several mechanisms have been identified in the aetiopathogenesis of heart
failure with preserved ejection fraction (HFpEF). Among these, coronary
microvascular dysfunction (CMD) may play a key pathophysiological role. We …
failure with preserved ejection fraction (HFpEF). Among these, coronary
microvascular dysfunction (CMD) may play a key pathophysiological role. We …
| | | |
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure
LA Allen - Heart Failure, 2024
Health status is the range of manifestation of disease in a given patient, including
symptoms, functional limitation, and quality of life, in which quality of life is the
discrepancy between actual and desired function. 1 In heart failure (HF), an often …
symptoms, functional limitation, and quality of life, in which quality of life is the
discrepancy between actual and desired function. 1 In heart failure (HF), an often …
| | | |
APPLICABILITY OF THE 2022 ACC/AHA/HFSA NATRIURETIC PEPTIDE CUTPOINTS FOR HEART FAILURE CLASSIFICATION IN OBESE INDIVIDUALS
M Chitsazan, J Parekh, L Kosyakovsky, ESW Lau… - Journal of the American …, 2024
Background Stage B heart failure (HF) represents a large population of individuals
with asymptomatic cardiac dysfunction. The 2022 ACC/AHA/HFSA HF guidelines
include elevated natriuretic peptide (NP) concentrations as part of the criteria for …
with asymptomatic cardiac dysfunction. The 2022 ACC/AHA/HFSA HF guidelines
include elevated natriuretic peptide (NP) concentrations as part of the criteria for …
| | | |
EFFECT OF DOACS VERSUS WARFARIN BY ASCVD STATUS IN 58,634 PATIENTS WITH ATRIAL FIBRILLATION: A POOLED ANALYSIS OF 4 RANDOMIZED …
A Zimerman, MG Palazzolo, SJ Connolly… - Journal of the American …, 2024
Background Patients with ASCVD and AF are at high risk for AF-related outcomes.
The efficacy and safety of DOACs vs warfarin (W) in pts with overt ASCVD, stratified
by arterial bed and including pts with prior MI/stroke, has not been well described …
The efficacy and safety of DOACs vs warfarin (W) in pts with overt ASCVD, stratified
by arterial bed and including pts with prior MI/stroke, has not been well described …
Okechukwu Ogah
Apr 13, 2024, 10:12:18 PMApr 13
to nigerian-car...@googlegroups.com
[HTML] Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A …
HC Chang, YY Chen, TT Kuo, YJ Lin, KL Chien… - Journal of the American …, 2024
Background This study investigated whether initial SGLT2 (sodium‐glucose
cotransporter 2) inhibitor‐based treatment is superior to metformin‐based regimens
as a primary prevention strategy among low‐risk patients with diabetes. Methods and …
cotransporter 2) inhibitor‐based treatment is superior to metformin‐based regimens
as a primary prevention strategy among low‐risk patients with diabetes. Methods and …
| | | |
[HTML] Association of intensive blood pressure management with cardiovascular outcomes in patients using multiple classes of antihypertensive medications: a post-hoc …
K Zhang, Q Song, J Bai, J Cai - Hypertension Research, 2024
High medication burden is associated with poor treatment effect and high risk of
cardiovascular outcomes. This study aimed to investigate the association between
the antihypertensive medication burden and cardiovascular outcomes in the STEP …
cardiovascular outcomes. This study aimed to investigate the association between
the antihypertensive medication burden and cardiovascular outcomes in the STEP …
| | | |
Direct Oral Anticoagulants Versus Vitamin K Antagonists for Left Ventricular Thrombi Management (P3-5.008)
P Mirpuri, S Khalid - Neurology, 2024
Objective: To compare the rates of ischemic stroke, major bleeding, transient
ischemic attack (TIA), and intracranial hemorrhage (ICH) through a matched analysis
of patients receiving DOACs or VKAs for left ventricular thrombus management …
ischemic attack (TIA), and intracranial hemorrhage (ICH) through a matched analysis
of patients receiving DOACs or VKAs for left ventricular thrombus management …
Okechukwu Ogah
Apr 18, 2024, 2:38:01 AMApr 18
to nigerian-car...@googlegroups.com
[PDF] Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
D D'Amario, R Laborante, E Bianchini, G Ciliberti… - ESC heart failure, 2024
Aims Several mechanisms have been identified in the aetiopathogenesis of heart
failure with preserved ejection fraction (HFpEF). Among these, coronary
microvascular dysfunction (CMD) may play a key pathophysiological role. We …
failure with preserved ejection fraction (HFpEF). Among these, coronary
microvascular dysfunction (CMD) may play a key pathophysiological role. We …
| | | |
Isolated left ventricular non-compaction cardiomyopathy: case report and brief review on diagnostic imaging methods
JV da Nóbrega Borges, SAC Leila… - Brazilian Journal of Case …, 2024
Left ventricular non-compaction cardiomyopathy (LVNC) is a rare congenital heart
disease with an estimated incidence of 0.014-0.045% in a general population. It
occurs due to a morphogenetic abnormality during embryogenesis that inhibits …
disease with an estimated incidence of 0.014-0.045% in a general population. It
occurs due to a morphogenetic abnormality during embryogenesis that inhibits …
| | | |
[HTML] Comparing the Real-World and Clinical Trial Bleeding Rates Associated with Oral Anticoagulation Treatment for Atrial Fibrillation
Y Gue, D Bloomfield, D Freedholm, GYH Lip - Journal of Clinical Medicine, 2024
Background The prevention of stroke in patients with atrial fibrillation (AF) involves
the use of oral anticoagulation, commonly in the form of direct oral anticoagulants
(DOACs). However, it comes with an increased risk of bleeding, and therefore …
the use of oral anticoagulation, commonly in the form of direct oral anticoagulants
(DOACs). However, it comes with an increased risk of bleeding, and therefore …
| | | |
[HTML] Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
JA Udell, MC Petrie, WS Jones, SD Anker, J Harrington… - Journal of the American …, 2024
Background Empagliflozin reduces the risk of heart failure (HF) hospitalizations but
not all-cause mortality when started within 14 days of acute myocardial infarction
(AMI). Objective To evaluate the association between left ventricular ejection fraction …
not all-cause mortality when started within 14 days of acute myocardial infarction
(AMI). Objective To evaluate the association between left ventricular ejection fraction …
| | | |
Response by Aggarwal et al to Letter Regarding Article,“Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With …
R Aggarwal, CT Ruff, S Virdone, S Perreault… - Circulation, 2024
Response by Aggarwal et al to Letter Regarding Article, “Development and Validation of
the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial
Fibrillation on Direct-Acting Oral Anticoagulants” | Circulation Science Volunteer …
the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial
Fibrillation on Direct-Acting Oral Anticoagulants” | Circulation Science Volunteer …
| | | |
VALIDATION OF THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE-23 IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY …
A Sawhney, A Nasri, EO Soles, H Zhao, A Sadek… - Journal of the American …, 2024
Background Chronic Thromboembolic Pulmonary Hypertension (CTEPH) produces
symptoms secondary to right heart failure, and one of the primary goal for treating
patients with CTEPH is to improve their symptoms, function, and quality of life (QoL) …
symptoms secondary to right heart failure, and one of the primary goal for treating
patients with CTEPH is to improve their symptoms, function, and quality of life (QoL) …
| | | |
[HTML] The Long Reach of Famine in Gaza
PF Clarkin
In 2015, Lital Keinan-Boker and colleagues published a study in The Israel Medical
Association Journal that examined whether the Holocaust during WW2 had impacted
the long-term health of older Israeli adults (mean age 69 years). They were working …
Association Journal that examined whether the Holocaust during WW2 had impacted
the long-term health of older Israeli adults (mean age 69 years). They were working …
Okechukwu Ogah
Apr 21, 2024, 12:09:13 PMApr 21
to nigerian-car...@googlegroups.com
Incremental value of diastolic wall strain in predicting heart failure events in patients with atrial fibrillation
N Taniguchi, Y Miyasaka, Y Suwa, E Nakai, S Harada… - Heart and Vessels, 2024
Diastolic wall strain (DWS), an echocardiographic index based on linear elasticity
theory, has been identified as a predictor of heart failure (HF) in patients with sinus
rhythm. However, its effectiveness in atrial fibrillation (AF) patients remains uncertain …
theory, has been identified as a predictor of heart failure (HF) in patients with sinus
rhythm. However, its effectiveness in atrial fibrillation (AF) patients remains uncertain …
| | | |
[PDF] Atrial Cardiomyopathy Predicts the Functional Outcome and Mortality in Stroke Patients
X Liu, Y Wang, L Ding, R Hu, Y Zhang, W Zhang, L Pei… - Journal of Atherosclerosis …, 2024
Aim: Atrial cardiomyopathy (ACM) is characterized by atrial dysfunction. This study
aims to assess the prognostic significance of ACM in patients with noncardioembolic
stroke (NCS). Methods: Patients with NCS within seven days of onset were …
aims to assess the prognostic significance of ACM in patients with noncardioembolic
stroke (NCS). Methods: Patients with NCS within seven days of onset were …
| | | |
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
S Chatur, BL Neuen, BL Claggett, IE Beldhuis… - Journal of the American …, 2024
STRUCTURED ABSTRACT Background The Kidney Disease Improving Global
Outcomes (KDIGO) classification integrates both estimated glomerular filtration rate
(eGFR) and urine-albumin-creatinine-ratio to stratify risk more comprehensively in …
Outcomes (KDIGO) classification integrates both estimated glomerular filtration rate
(eGFR) and urine-albumin-creatinine-ratio to stratify risk more comprehensively in …
| | | |
Post-diuretic spot urine sodium assessment in acute heart failure: a retrospective analysis
L Colson, S Vanhentenrijk, T Kalpakos, B Roosens… - Acta Clinica Belgica, 2024
Aims To provide real-world data on post-diuretic spot urine sodium concentration
(UNa) assessment in acute heart failure (AHF) and its implications for treatment.
Methods and Results Automated query of the electronic medical record identified …
(UNa) assessment in acute heart failure (AHF) and its implications for treatment.
Methods and Results Automated query of the electronic medical record identified …
Okechukwu Ogah
Apr 21, 2024, 12:09:31 PMApr 21
to nigerian-car...@googlegroups.com
[HTML] Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial
S Selvaraj, S Patel, AJ Sauer, RW McGarrah, P Jones… - JACC: Heart Failure, 2024
Background Although sodium glucose co-transporter 2 inhibitors (SGLT2is) improve
heart failure (HF)-related symptoms and outcomes in HF with preserved ejection
fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced EF …
heart failure (HF)-related symptoms and outcomes in HF with preserved ejection
fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced EF …
| | | |
[HTML] Retinal Vascular Changes in Heart Failure with Preserved Ejection Fraction Using Optical Coherence Tomography Angiography
J Weerts, AG Raafs, B Sandhoefner… - Journal of Clinical Medicine, 2024
Background: Systemic microvascular regression and dysfunction are considered
important underlying mechanisms in heart failure with preserved ejection fraction
(HFpEF), but retinal changes are unknown. Methods: This prospective study aimed to …
important underlying mechanisms in heart failure with preserved ejection fraction
(HFpEF), but retinal changes are unknown. Methods: This prospective study aimed to …
| | | |
Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
JD Roh, C Castro, A Yu, S Rana, S Shahul, KJ Gray… - Science Translational …, 2024
Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced
heart failure associated with preeclampsia. Circulating factors in late pregnancy are
thought to contribute to both diseases, suggesting a common underlying …
heart failure associated with preeclampsia. Circulating factors in late pregnancy are
thought to contribute to both diseases, suggesting a common underlying …
Okechukwu Ogah
Apr 22, 2024, 10:27:10 AMApr 22
to nigerian-car...@googlegroups.com
[HTML] Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction
C Carland, L Zhao, O Salman, JB Cohen, P Zamani… - Journal of the American …, 2024
Background Although several studies have addressed plasma proteomics in heart
failure with preserved ejection fraction, limited data are available on the prognostic
value of urinary proteomics. The objective of our study was to identify urinary …
failure with preserved ejection fraction, limited data are available on the prognostic
value of urinary proteomics. The objective of our study was to identify urinary …
| | | |
TWO-WEEK KETONE ESTER TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: EFFECTS ON …
N Gopalasingam, K Berg-Hansen, KH Christensen… - Journal of the American …, 2024
Background Heart failure with preserved ejection fraction (HFpEF) is a major cause
of morbidity and mortality in patients with type 2 diabetes (T2D). The ketone body 3-
hydroxybutyrate exerts beneficial acute hemodynamic effects in non-T2D patients …
of morbidity and mortality in patients with type 2 diabetes (T2D). The ketone body 3-
hydroxybutyrate exerts beneficial acute hemodynamic effects in non-T2D patients …
| | | |
RIGHT VENTRICULAR SYSTOLIC PRESSURE IS A SIGNIFICANT DETERMINANT OF EXCESS BLEEDING IN PEOPLE WITH NONVALVULAR ATRIAL …
MP O'Shea, A Yusuf, CJ Chao, SN Ravi… - Journal of the American …, 2024
Background Direct oral anticoagulants (DOACs) are increasingly used for stroke
prevention in non-valvular atrial fibrillation (NVAF). Rivaroxaban and dabigatran
have higher reported bleeding rates than apixaban. Pulmonary hypertension (PH) is …
prevention in non-valvular atrial fibrillation (NVAF). Rivaroxaban and dabigatran
have higher reported bleeding rates than apixaban. Pulmonary hypertension (PH) is …
| | | |
COMPARATIVE EFFECTIVENESS OF SACUBITRIL/VALSARTAN VERSUS ACEI/ARB AMONG> 80,000 PATIENTS WITH DE NOVO HEART FAILURE WITH …
A Bhatt, M Vaduganathan, B Jena, S Suminska, C Eid… - Journal of the American …, 2024
Background Real world use of sacubitril/valsartan [S/V] and association with clinical
outcomes in newly diagnosed (de novo) patients with HFmrEF/HFpEF (LVEF> 40%)
have been incompletely studied. Methods In a retrospective, propensity-matched …
outcomes in newly diagnosed (de novo) patients with HFmrEF/HFpEF (LVEF> 40%)
have been incompletely studied. Methods In a retrospective, propensity-matched …
| | | |
Contemporary trends in incident ischemic stroke, intracranial hemorrhage, and mortality in individuals with atrial fibrillation
JJ Noubiap, JJ Tang, TA Dewland, GM Marcus - … Heart Journal-Quality of Care and …, 2024
Background The prognosis for atrial fibrillation (AF) patients is based on data that is
decades old. Given evolving standards of clinical practice, we sought to evaluate
temporal trends in clinically important outcomes among patients with AF. Methods …
decades old. Given evolving standards of clinical practice, we sought to evaluate
temporal trends in clinically important outcomes among patients with AF. Methods …
| | | |
[HTML] Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
X Ni, X Feng, Z Wang, Y Zhang, PJ Little, Y Cao, S Xu… - Acta Pharmacologica Sinica, 2024
Heart failure with preserved ejection fraction (HFpEF) is closely associated with
metabolic derangement. Sodium glucose cotransporter-2 inhibitors (SGLT2i) and
glucagon-like peptide-1 receptor agonists (GLP-1RA) exert anti-HFpEF effects, but …
metabolic derangement. Sodium glucose cotransporter-2 inhibitors (SGLT2i) and
glucagon-like peptide-1 receptor agonists (GLP-1RA) exert anti-HFpEF effects, but …
| | | |
[HTML] Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure in India: A Retrospective Real-world (SAVE) Study
A Sachdeva, A Shukla, M Mayabhate, N Kapure - Indian Journal of Clinical …, 2024
Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF)
management. Little is known about its uses or impact in real-world practice in the
Indian population. We evaluated the effectiveness and Safety of Sacubitril/Valsartan …
management. Little is known about its uses or impact in real-world practice in the
Indian population. We evaluated the effectiveness and Safety of Sacubitril/Valsartan …
| | | |
ELECTRONIC ALERTS TO IMPROVE MINERALOCORTICOID RECEPTOR ANTAGONIST USE AND HYPERKALEMIA MANAGEMENT IN AMBULATORY PATIENTS …
K Clark, A Victoria-Castro, L Ghazi, Y Yamamoto… - Journal of the American …, 2024
Background Despite overwhelming evidence of clinical benefit for patients with heart
failure with reduced ejection fraction (HFrEF), mineralocorticoid antagonists (MRAs)
continue to be underused. Methods PROMPT-MRA (PRagmatic trial Of Messaging to …
failure with reduced ejection fraction (HFrEF), mineralocorticoid antagonists (MRAs)
continue to be underused. Methods PROMPT-MRA (PRagmatic trial Of Messaging to …
| | | |
Treatment patterns of patients with worsening heart failure with reduced ejection fraction.
SJ Greene, HK Gaggin, M Zhou, LD Bash, D Lautsch… - ESC Heart Failure, 2024
Aims Patients with HFrEF and worsening HF events (WHFE) are at particularly high
risk and urgently need disease-modifying therapy. CHART-HF assessed treatment
patterns and reasons for medication decisions among HFrEF patients with and …
risk and urgently need disease-modifying therapy. CHART-HF assessed treatment
patterns and reasons for medication decisions among HFrEF patients with and …
| | | |
ADVERSE EVENTS RELATED TO SACUBITRIL/VALSARTAN IN ELDERLY PATIENTS: INSIGHTS FROM REVIEW-HF REGISTRY
R Wada, R Nakanishi, T Ikeda, T Nasu, S Ishii… - Journal of the American …, 2024
Background Although sacubitril/valsartan is known to be effective in patients with
heart failure (HF), the tolerability and safety of this drug in elderly patients remain
unclear. Methods As a post-hoc analysis of a Japanese multicenter study including …
heart failure (HF), the tolerability and safety of this drug in elderly patients remain
unclear. Methods As a post-hoc analysis of a Japanese multicenter study including …
Okechukwu Ogah
Apr 26, 2024, 3:58:01 AMApr 26
to nigerian-car...@googlegroups.com
[PDF] Age‐stratified profiles and outcomes of patients with heart failure with preserved ejection fraction
S Yamanaka, K Nochioka, H Hayashi, T Shiroto… - ESC Heart Failure, 2024
Aims This study aimed to elucidate age‐stratified clinical profiles and outcomes in
patients with heart failure (HF) with preserved left ventricular ejection fraction
(LVEF)(HFpEF). Methods and results The Chronic Heart Failure Registry and …
patients with heart failure (HF) with preserved left ventricular ejection fraction
(LVEF)(HFpEF). Methods and results The Chronic Heart Failure Registry and …
| | | |
TWO-WEEK KETONE ESTER TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: EFFECTS ON …
N Gopalasingam, K Berg-Hansen, KH Christensen… - Journal of the American …, 2024
Background Heart failure with preserved ejection fraction (HFpEF) is a major cause
of morbidity and mortality in patients with type 2 diabetes (T2D). The ketone body 3-
hydroxybutyrate exerts beneficial acute hemodynamic effects in non-T2D patients …
of morbidity and mortality in patients with type 2 diabetes (T2D). The ketone body 3-
hydroxybutyrate exerts beneficial acute hemodynamic effects in non-T2D patients …
| | | |
Synergistic effect of spironolactone/ARB on cardiovascular endpoints in heart failure patients with preserved ejection
X Liu, Y Wang, K Yiu, Y Zhang, J Wang - European journal of internal medicine, 2024
Synergistic effect of spironolactone/ARB on cardiovascular endpoints in heart failure
patients with preserved ejection Synergistic effect of spironolactone/ARB on
cardiovascular endpoints in heart failure patients with preserved ejection Eur J …
patients with preserved ejection Synergistic effect of spironolactone/ARB on
cardiovascular endpoints in heart failure patients with preserved ejection Eur J …
| | | |
Impact of Outpatient Beta Blocker Therapy Adjustment on Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction Admitted for Acute …
RW Bok, JL Lacoste, W Fang, K Kido - Journal of Pharmacy Practice, 2024
Background: Limited data exists to evaluate the optimal management of outpatient
beta blocker therapy when patients with heart failure with reduced ejection fraction
(HFrEF) are admitted for acute decompensated heart failure (ADHF). Objective: This …
beta blocker therapy when patients with heart failure with reduced ejection fraction
(HFrEF) are admitted for acute decompensated heart failure (ADHF). Objective: This …
| | | |
[PDF] Uncontrolled hypertension is associated with an increased risk of end-stage renal disease in patients with type 2 diabetes who underwent postpercutaneous coronary …
H Kim, YM Park, SH Ko, YJ Cho, HW Kim, YK Kim… - medRxiv, 2024
Background: Little is known about the use of hypertension to predict end-stage renal
disease (ESRD) in patients with type 2 diabetes mellitus (T2DM) and established
coronary artery disease who underwent percutaneous coronary intervention (PCI) …
disease (ESRD) in patients with type 2 diabetes mellitus (T2DM) and established
coronary artery disease who underwent percutaneous coronary intervention (PCI) …
| | | |
TRENDS AND OUTCOMES ASSOCIATED WITH THE USE OF NOVEL ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH CARDIAC THROMBUS …
A Albaeni, Y SHAN, RA Thakker, R Saxena… - Journal of the American …, 2024
Background Cardiac thrombus after ST-segment elevation myocardial infarction
(STEMI) is a serious complication that can lead to catastrophic consequences such
as ischemic stroke and death. We analyzed the 100% Texas Medicare database to …
(STEMI) is a serious complication that can lead to catastrophic consequences such
as ischemic stroke and death. We analyzed the 100% Texas Medicare database to …
| | | |
Response by Aggarwal et al to Letter Regarding Article,“Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With …
R Aggarwal, CT Ruff, S Virdone, S Perreault… - Circulation, 2024
Response by Aggarwal et al to Letter Regarding Article, “Development and Validation of
the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial
Fibrillation on Direct-Acting Oral Anticoagulants” | Circulation Science Volunteer …
the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial
Fibrillation on Direct-Acting Oral Anticoagulants” | Circulation Science Volunteer …
Okechukwu Ogah
Apr 28, 2024, 2:32:33 PMApr 28
to nigerian-car...@googlegroups.com
[HTML] Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide
C Liu, Q Long, H Yang, H Yang, Y Tang, B Liu, Z Zhou… - Biomedicine & …, 2024
Studies have shown that Sacubitril/valsartan (Sac/Val) can reduce myocardial
inflammation in myocarditis mice, in addition to its the recommended treatment of
heart failure. However, the underlying mechanisms of Sac/Val in myocarditis remain …
inflammation in myocarditis mice, in addition to its the recommended treatment of
heart failure. However, the underlying mechanisms of Sac/Val in myocarditis remain …
| | | |
[HTML] Impaired fibrinolysis in patients with atrial fibrillation and elevated circulating lipopolysaccharide
M Sadowski, M Ząbczyk, A Undas - Journal of Thrombosis and Thrombolysis, 2024
It is unknown whether elevated gut-derived serum lipopolysaccharide (LPS) can
affect thrombin generation, fibrinolysis, and fibrin clot properties in atrial fibrillation
(AF). We aimed to evaluate associations of circulating LPS with prothrombotic …
affect thrombin generation, fibrinolysis, and fibrin clot properties in atrial fibrillation
(AF). We aimed to evaluate associations of circulating LPS with prothrombotic …
| | | |
[PDF] Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Saudi Patients With Atrial Fibrillation
M Almegren - Cureus, 2024
Introduction: Atrial fibrillation (AF) significantly heightens stroke risk, which can be
mitigated through anticoagulation therapy. Although warfarin was traditionally
employed for this purpose, the use of directacting oral anticoagulants (DOACs) is on …
mitigated through anticoagulation therapy. Although warfarin was traditionally
employed for this purpose, the use of directacting oral anticoagulants (DOACs) is on …
| | | |
[HTML] The cardiovascular safety of sodium nitroprusside in acute heart failure
PP Bocchino, F Angelini, G Gallone, S Frea… - Expert Opinion on Drug …, 2024
Sodium nitroprusside (SNP) is a short-acting, light-sensitive, intravenous vasodilator
consisting of a complex dianion [Fe (CN) 5NO] 2–in which an octahedral iron center
is surrounded by five cyanide ligands and one linear nitric oxide ligand [1]. Its …
consisting of a complex dianion [Fe (CN) 5NO] 2–in which an octahedral iron center
is surrounded by five cyanide ligands and one linear nitric oxide ligand [1]. Its …
| | | |
EFFECTS OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK
S Chatur, B Claggett, FM Causland, M Packer… - Journal of the American …, 2024
Background Heart failure and CKD frequently coexist, increasing the risk for CV
events and progression to ESRD. Kidney Disease Improving Global Outcomes
(KDIGO) integrates eGFR and urine albumin-to-creatinine ratio (UACR) to risk stratify …
events and progression to ESRD. Kidney Disease Improving Global Outcomes
(KDIGO) integrates eGFR and urine albumin-to-creatinine ratio (UACR) to risk stratify …
Okechukwu Ogah
May 2, 2024, 9:03:31 PMMay 2
to nigerian-car...@googlegroups.com
[PDF] Subclinical Hypothyroidism Predicted Adverse Cardiovascular Events in Patients with Ejection Fraction Preserved Heart Failure
Q Tan, M Chen, H Yang, Y Guo, X Zou - Therapeutics and Clinical Risk Management, 2024
Background Subclinical hypothyroidism (SH) increases the risk of cardiovascular
events, however the influence of SH on prognosis of ejection fraction preserved heart
failure (HFpEF) is not fully understood. Methods In this prospective observational …
events, however the influence of SH on prognosis of ejection fraction preserved heart
failure (HFpEF) is not fully understood. Methods In this prospective observational …
| | | |
Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study
P Kirchhof, A Bakhai, C de Asmundis, JR de Groot… - International Journal of …, 2024
Background To assess long-term effectiveness and safety of edoxaban in Europe.
Methods and results ETNA-AF-Europe, a prospective, multinational, multi-centre,
post-authorisation, observational study was conducted in agreement with the …
Methods and results ETNA-AF-Europe, a prospective, multinational, multi-centre,
post-authorisation, observational study was conducted in agreement with the …
| | | |
[PDF] The Impact of Coronary Artery Disease on Outcomes in Patients With Peripartum Cardiomyopathy
O Elkattawy, JV Phansalkar, S Elkattawy, O Mohamed… - Cureus, 2024
The purpose of this study was to determine the prevalence of coronary artery disease
(CAD) among patients admitted with peripartum cardiomyopathy (PPCM) as well as
to analyze the independent association of CAD with in-hospital outcomes among …
(CAD) among patients admitted with peripartum cardiomyopathy (PPCM) as well as
to analyze the independent association of CAD with in-hospital outcomes among …
| | | |
[PDF] Effectiveness of Anticoagulants in Reducing Stroke Risk Among Patients With Atrial Fibrillation
SN Dasari, ST Gadde, P Myneni, M Bodduluri… - Cureus, 2024
Atrial fibrillation (AF) is a type of cardiac arrhythmia causing shortness of breath,
lightheadedness, and palpitations. It may go unrecognized and asymptomatic among
many patients. AF is not a potentially fatal arrhythmia; its hemodynamic, structural …
lightheadedness, and palpitations. It may go unrecognized and asymptomatic among
many patients. AF is not a potentially fatal arrhythmia; its hemodynamic, structural …
Okechukwu Ogah
May 7, 2024, 11:27:06 AMMay 7
to nigerian-car...@googlegroups.com
[HTML] Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry
JP Bae, L Kallenbach, DR Nelson, K Lavelle… - BMC Endocrine Disorders, 2024
Background The proportion of heart failure patients with preserved ejection fraction
has been rising over the past decades and has coincided with increases in the
prevalence of obesity and metabolic syndrome. The relationship between these …
has been rising over the past decades and has coincided with increases in the
prevalence of obesity and metabolic syndrome. The relationship between these …
| | | |
[PDF] Improving therapeutic outcomes in heart failure with reduced nonvalvular ejection fraction: A clinical study of heart failure education intervention
X Tian, X Li, Q Zhang, X Qiao, X Li, Z Zhang - Clinical Cardiology, 2024
Objective The current study delves into the impact of heart failure education
intervention on improving therapeutic outcomes for heart failure (HF) patients with
reduced nonvalvular ejection fraction. Methods There involved a total of 60 HF …
intervention on improving therapeutic outcomes for heart failure (HF) patients with
reduced nonvalvular ejection fraction. Methods There involved a total of 60 HF …
| | | |
Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study
U Zeymer, R Groves, S Hupfer - Herz, 2024
Abstract Background Sacubitril/valsartan (Sac/Val) is the first angiotensin receptor-
neprilysin inhibitor indicated for symptomatic chronic heart failure (HF) with reduced
ejection fraction (HFrEF). Given most patients with HF in Germany are managed by …
neprilysin inhibitor indicated for symptomatic chronic heart failure (HF) with reduced
ejection fraction (HFrEF). Given most patients with HF in Germany are managed by …
| | | |
Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to …
H Yin, L Ma, Y Zhou, X Tang, R Li, Y Zhou, J Shi… - Heart and Vessels, 2024
Abstract Effects of angiotensin receptor/neprilysin inhibitors (ARNI) on ventricular
remodeling in patients with heart failure, especially heart failure with reduced
ejection fraction (HFrEF), are better than those of angiotensin-converting enzyme …
remodeling in patients with heart failure, especially heart failure with reduced
ejection fraction (HFrEF), are better than those of angiotensin-converting enzyme …
| | | |
[PDF] Representativeness of the PIONEER‐HF and PARAGLIDE‐HF in patients hospitalized with acute heart failure
DY Chen, CC Chen, CH Lee, CN Tseng, SW Chen… - ESC Heart Failure, 2024
Abstract Aims The PIONEER‐HF and PARAGLIDE‐HF trials aimed to determine the
efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients
hospitalized for AHF. However, whether the inclusion and exclusion criteria of the …
efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients
hospitalized for AHF. However, whether the inclusion and exclusion criteria of the …
| | | |
[HTML] Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general …
PA Cortesi, IC Antonazzo, P Palladino, M Gnesi… - Acta Diabetologica, 2024
Aim In 2022, in Italy, general practitioners (GPs) have been allowed to prescribe
SGLT2i in Type 2 Diabetes (T2D) under National Health Service (NHS)
reimbursement. In the pivotal clinical trial named DECLARE-TIMI 58, dapagliflozin …
SGLT2i in Type 2 Diabetes (T2D) under National Health Service (NHS)
reimbursement. In the pivotal clinical trial named DECLARE-TIMI 58, dapagliflozin …
Okechukwu Ogah
May 10, 2024, 10:46:41 AMMay 10
to nigerian-car...@googlegroups.com
[PDF] The effect of sustained-release CARvedilol in patients with hypErtension and heart failure with preserved ejection fraction: a study protocol for a pilot randomized …
M Yoon, SJ Park, BS Yoo, DJ Choi - Frontiers in Cardiovascular Medicine, 2024
Background Although beta-blockers improve clinical outcomes in heart failure with
reduced ejection fraction, the benefit of beta-blockers in heart failure with preserved
ejection fraction (HFpEF) is uncertain. Global longitudinal strain (GLS) is a robust …
reduced ejection fraction, the benefit of beta-blockers in heart failure with preserved
ejection fraction (HFpEF) is uncertain. Global longitudinal strain (GLS) is a robust …
| | | |
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart …
E Núñez, E Santas, H Merenciano… - European Journal of Heart …, 2024
Aims There is limited information on the sex‐specific longitudinal changes of left
ventricular ejection fraction (LVEF) after an acute heart failure (AHF) hospitalization.
We aimed to investigate whether LVEF trajectories over time and their impact on …
ventricular ejection fraction (LVEF) after an acute heart failure (AHF) hospitalization.
We aimed to investigate whether LVEF trajectories over time and their impact on …
| | | |
Effects of Sacubitril/Valsartan on Functional Capacity in Real-World Patients in Italy: The REAL. IT Study in Heart Failure with Reduced Ejection Fraction
FM Sarullo, C Nugara, S Sarullo, M Iacoviello… - Frontiers in Cardiovascular …
Background. Heart failure (HF) significantly affects morbidity, mortality, and quality of
life of patients. New therapeutic strategies aim to improve patients' functional
capacity and quality of life while controlling HF-related risks. Real-world data on both …
life of patients. New therapeutic strategies aim to improve patients' functional
capacity and quality of life while controlling HF-related risks. Real-world data on both …
| | | |
[PDF] Role of brain natriuretic peptide as an indicator for reverse remodeling of left ventricular systolic dysfunction after introduction of sacubitril/valsartan in patients with …
MI Abdelhalim, KA Elsharnouby, MZ El Amrousy… - IJCS, 2024
Background: Chronic heart failure (CHF) is a clinical syndrome that occurs because
of mechanical dysfunction, molecular and inflammatory changes of the left ventricle.
Aims: This study aimed to investigate the effect of Sacubitril/Valsartan on remodelling …
of mechanical dysfunction, molecular and inflammatory changes of the left ventricle.
Aims: This study aimed to investigate the effect of Sacubitril/Valsartan on remodelling …
| | | |
[PDF] Sodium-glucose co-transporter 2 Inhibitors Act Independently of SGLT2 to Confer Benefit for Heart Failure with Reduced Ejection Fraction in Mice
JH Berger, TR Matsuura, CE Bowman, R Taing, J Patel… - bioRxiv, 2024
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are novel, potent heart failure
medications with an unknown mechanism of action. We sought to determine if the
beneficial actions of SGLT2i in heart failure were on-or off-target, and related to …
medications with an unknown mechanism of action. We sought to determine if the
beneficial actions of SGLT2i in heart failure were on-or off-target, and related to …
| | | |
[PDF] Effect of sacubutril/valsartan and dapagliflozin on athletic performance; Can the popular cardiac medications of recent years be used as doping agents?
A Torun, S Kilic, S Asal, M Babaoglu, S Yavuz… - Authorea Preprints, 2024
Studies conducted in recent years have demonstrated the positive effects of
sacubitril/valsartan and dapagliflozin on cardiac prognosis and performance. These
drugs can potentially be abused as doping agents by professional athletes. In our …
sacubitril/valsartan and dapagliflozin on cardiac prognosis and performance. These
drugs can potentially be abused as doping agents by professional athletes. In our …
Okechukwu Ogah
May 10, 2024, 10:48:44 AMMay 10
to nigerian-car...@googlegroups.com
[PDF] The role of sodium glucose cotransporter or glucagon-like peptide-1 receptor agonists in treating heart failure with preserved ejection fraction in patients with type 2 …
L LUNGEANU-JURAVLE, M TACHE, A RADU… - Romanian JouRnal of …, 2024
Background. Heart failure with preserved ejection fraction is not a single disease but
a clinical syndrome secondary to important comorbidities, is increasing in
prevalence, and is associated with high functional impairment. This study aimed to …
a clinical syndrome secondary to important comorbidities, is increasing in
prevalence, and is associated with high functional impairment. This study aimed to …
| | | |
Sacubitril/valsartan as an effective hypertension treatment option in those with chronic type B aortic dissection
MG Buhnerkempe, S Bitner, JM Flack - American Journal of Hypertension, 2024
Aortic dissection (AD) impacts around 4.8 per 100,000 individuals per year1. Intimal
tears in the descending aorta, Stanford type B aortic dissections (TBAD), account for
25–40% of aortic dissections and are associated with relatively high 30-day mortality …
tears in the descending aorta, Stanford type B aortic dissections (TBAD), account for
25–40% of aortic dissections and are associated with relatively high 30-day mortality …
| | | |
Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry
T Murakami, Y Watanabe, N Nakamura, M Natsumeda… - Heart and Vessels, 2024
Background Severe aortic valve stenosis (AS) and atrial fibrillation (AF) are risk
factors of hemodynamic instability in heart failure (HF) management due to low
cardiac output, respectively. Therefore, the treatment of HF due to severe AS …
factors of hemodynamic instability in heart failure (HF) management due to low
cardiac output, respectively. Therefore, the treatment of HF due to severe AS …
| | | |
[PDF] Representativeness of the PIONEER‐HF and PARAGLIDE‐HF in patients hospitalized with acute heart failure
DY Chen, CC Chen, CH Lee, CN Tseng, SW Chen… - ESC Heart Failure, 2024
Abstract Aims The PIONEER‐HF and PARAGLIDE‐HF trials aimed to determine the
efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients
hospitalized for AHF. However, whether the inclusion and exclusion criteria of the …
efficacy and safety of the in‐hospital initiation of sacubitril/valsartan in patients
hospitalized for AHF. However, whether the inclusion and exclusion criteria of the …
| | | |
[PDF] Effectiveness of Dapagliflozin in Reducing Incidence of Worsening Heart Failure Events among patients with Reduced Ejection Fraction
M Asif, T Laique - Pakistan Journal of Medical & Health Sciences, 2024
Background: Sodium–glucose co-transporter 2 (SGLT2) inhibitors are the groups of
oral hypoglycemics that decreases the worse events among cardiac patients of
chronic heart failure. Aim: To assess the effectiveness of Dapagliflozin in reducing …
oral hypoglycemics that decreases the worse events among cardiac patients of
chronic heart failure. Aim: To assess the effectiveness of Dapagliflozin in reducing …
Okechukwu Ogah
May 12, 2024, 12:25:18 PMMay 12
to nigerian-car...@googlegroups.com
[HTML] Etiology and phenotypes of cardiomyopathy in Southern Africa: the IMHOTEP multicenter pilot study
SM Kraus, J Cirota, S Pandie, K Thomas, M Thomas… - JACC: Advances, 2024
Background Cardiomyopathies are an important cause of heart failure in Africa yet
there are limited data on etiology and clinical phenotypes. Objectives The IMHOTEP
(African Cardiomyopathy and Myocarditis Registry Program) was designed to …
there are limited data on etiology and clinical phenotypes. Objectives The IMHOTEP
(African Cardiomyopathy and Myocarditis Registry Program) was designed to …
| | | |
[HTML] Trajectories of sacubitril/valsartan adherence among Medicare beneficiaries with heart failure
W Huang, MM Ahmed, EJ Morris, L Yang, L O'Neal… - JACC: Advances, 2024
Background Sacubitril/valsartan, an angiotensin receptor/neprilysin inhibitor (ARNi),
improves heart failure (HF) outcomes, yet real-world adherence patterns are not well
understood. Objectives The purpose of this study was to analyze longitudinal …
improves heart failure (HF) outcomes, yet real-world adherence patterns are not well
understood. Objectives The purpose of this study was to analyze longitudinal …
Okechukwu Ogah
May 16, 2024, 5:55:36 PMMay 16
to nigerian-car...@googlegroups.com
Heart Failure with Normal Natriuretic Peptide Levels and Preserved Ejection Fraction: A Prospective Clinical and Cardiac MRI Study
J He, W Yang, W Wu, G Yin, B Zhuang, J Xu, D Zhou… - Radiology: Cardiothoracic …, 2024
Purpose To describe the clinical presentation, comprehensive cardiac MRI
characteristics, and prognosis of individuals with predisposed heart failure with
preserved ejection fraction (HFpEF). Materials and Methods This prospective cohort …
characteristics, and prognosis of individuals with predisposed heart failure with
preserved ejection fraction (HFpEF). Materials and Methods This prospective cohort …
| | | |
Elevated sympathetic-mediated vasoconstriction at rest but intact functional sympatholysis during exercise in heart failure with reduced ejection fraction
NG Boyes, MR Khan, AMS Luchkanych, RA Marshall… - American Journal of …, 2024
Background: Patients with heart failure with reduced ejection fraction (HFrEF) have
exaggerated sympathoexcitation and impaired peripheral vascular conductance.
Evidence demonstrating consequent impaired functional sympatholysis is limited in …
exaggerated sympathoexcitation and impaired peripheral vascular conductance.
Evidence demonstrating consequent impaired functional sympatholysis is limited in …
| | | |
Small left ventricle in patients with atrial fibrillation is associated with increased cardiovascular risk
M Li, L Ren, L He, Y Lai, J Wang, S Li, X Peng, M Zhao… - Journal of the American …, 2024
Background It is still unclear whether small left ventricle (LV) is an adverse structural
prognostic feature in patients with atrial fibrillation (AF). Objectives The purpose of
this study was to evaluate the association between small LV and risk of …
prognostic feature in patients with atrial fibrillation (AF). Objectives The purpose of
this study was to evaluate the association between small LV and risk of …
| | | |
[HTML] Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 …
Y Zhao, Z Lu, H Zhang, L Wang, F Sun, Q Li, T Cao… - Journal of Advanced …, 2024
Introduction Excess salt intake is not only an independent risk factor for heart failure,
but also one of the most important dietary factors associated with cardiovascular
disease worldwide. Metabolic reprogramming in cardiomyocytes is an early event …
but also one of the most important dietary factors associated with cardiovascular
disease worldwide. Metabolic reprogramming in cardiomyocytes is an early event …
| | | |
[PDF] Optimal Strategies to Select Warfarin Dose for Thai Patients with Atrial Fibrillation
A Ujjin, W Wongcharoen, A Suwanagool… - Journal of Clinical Medicine, 2024
Background: Warfarin has been the mainstay treatment for the prevention of stroke
and systemic thromboembolism in patients with atrial fibrillation (AF). The optimal
starting dose of warfarin remains unclear. Objective: To investigate the most optimal …
and systemic thromboembolism in patients with atrial fibrillation (AF). The optimal
starting dose of warfarin remains unclear. Objective: To investigate the most optimal …
| | | |
Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function
S Matsumoto, AD Henderson, L Shen, M Yang… - Journal of the American …, 2024
Background Kidney dysfunction often leads to reluctance to start or continue life-
saving heart failure (HF) therapy. Objectives This study sought to examine the
efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with …
saving heart failure (HF) therapy. Objectives This study sought to examine the
efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with …
| | | |
[HTML] Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
SJ Shah, K Sharma, BA Borlaug, J Butler, M Davies… - European Heart Journal, 2024
Abstract Background and Aims In the STEP-HFpEF trial program, treatment with
semaglutide resulted in multiple beneficial effects in patients with obesity-related
heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to …
semaglutide resulted in multiple beneficial effects in patients with obesity-related
heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to …
| | | |
Dual Antithrombotic Therapy Versus Anticoagulant Monotherapy for Major Adverse Limb Events in Patients with Concomitant Lower Extremity Arterial Disease and …
DSH Lin, HP Wu, WJ Chung, SK Hsueh, PC Hsu… - European Journal of Vascular and …
Objective Patients with symptomatic lower extremity arterial disease (LEAD) are
recommended to receive antiplatelet therapy, while direct oral anticoagulants
(DOAC) are standard for stroke prevention in atrial fibrillation (AF). For patients with …
recommended to receive antiplatelet therapy, while direct oral anticoagulants
(DOAC) are standard for stroke prevention in atrial fibrillation (AF). For patients with …
| | | |
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis
JW Ostrominski, BL Claggett, ZM Miao… - Journal of the American …, 2024
Cardiovascular, kidney, and metabolic (CKM) conditions, such as atherosclerotic
cardiovascular disease (ASCVD), chronic kidney disease (CKD), and type 2 diabetes
(DM), are leading and pathophysiologically inter-related causes of death and …
cardiovascular disease (ASCVD), chronic kidney disease (CKD), and type 2 diabetes
(DM), are leading and pathophysiologically inter-related causes of death and …
Reply all
Reply to author
Forward
0 new messages